CELG Celgene Corporation

   By Josh Beckerman 
 

Celgene Corp. said a Phase 3 trial of its blood-cancer drug Revlimid with lymphoma patients didn't meet a key secondary endpoint.

The study is part of a broad research program focused on multiple areas of non-Hodgkin lymphoma. Revlimid has been projected to post $8 billion of sales this year, a majority of Celgene's revenue.

Celgene said Monday that the study, known as REMARC, evaluated maintenance therapy with Revlimid compared with a placebo in diffuse large B-cell lymphoma patients responding to first-line rituximab plus CHOP chemotherapy induction therapy.

The trial met its primary endpoint of statistically significant improvement in progression-free survival, but an interim analysis of overall survival showed no benefit, Celgene said. As a result, Celgene won't pursue approval for this indication.

Celgene shares fell 2.8% to $104.87 in after-hours trading.

Data from the other non-Hodgkin lymphoma trials are expected in 2017.

Celgene, based in Summit, N.J., has expanded beyond its roots in the multiple myeloma market. In August, it bought Receptos for $7.2 billion, a bid to move deeper into the market for autoimmune diseases.

Last year, Celgene and Juno Therapeutics Inc. announced a 10-year collaboration focused on treatments for cancer and autoimmune diseases. Celgene invested about $1 billion in Juno initially, including an $849.8 million stock purchase and a $150 million payment.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 25, 2016 19:39 ET (23:39 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.